Associations of MYC protein expression and gene status with breast cancer subtypes and outcome in patients treated with anthracycline-based adjuvant chemotherapy

被引：0
|
作者：
Batistatou, A.
Razis, E.
Bobos, M.
Tsolaki, E.
Timotheadou, E.
Alexopoulou, Z.
Goussia, A.
Gogas, H.
Koutras, A.
Karina, M.
Pentheroudakis, G.
Efstratiou, I.
Petraki, K.
Sotiropoulou, M.
Pavlakis, K.
Koletsa, T.
Kotoula, V.
Fountzilas, G.
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Athens, Greece
[2] Hlth Data Specialists Ltd, Athens, Greece
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-08-50
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-50
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
    Jensen, Maj-Britt
    Laenkholm, Anne-Vibeke
    Balslev, Eva
    Buckingham, Wesley
    Ferree, Sean
    Glavicic, Vesna
    Jensen, Jeanette Dupont
    Knoop, Ann Soegaard
    Mouridsen, Henning T.
    Nielsen, Dorte
    Nielsen, Torsten O.
    Ejlertsen, Bent
    NPJ BREAST CANCER, 2020, 6 (01)
  • [32] Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Mano, MS
    Awada, A
    Kerr, J
    Canney, P
    CANCER TREATMENT REVIEWS, 2005, 31 (02) : 69 - 78
  • [33] Optimum anthracycline-based chemotherapy for early breast cancer
    Adlard, Julian W.
    Dodwell, David J.
    LANCET ONCOLOGY, 2001, 2 (08): : 469 - 474
  • [34] Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
    Schindlbeck, Christian
    Mayr, D.
    Olivier, C.
    Rack, B.
    Engelstaedter, V.
    Jueckstock, J.
    Jenderek, C.
    Andergassen, U.
    Jeschke, U.
    Friese, K.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 1029 - 1037
  • [35] Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
    Christian Schindlbeck
    D. Mayr
    C. Olivier
    B. Rack
    V. Engelstaedter
    J. Jueckstock
    C. Jenderek
    U. Andergassen
    U. Jeschke
    K. Friese
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1029 - 1037
  • [36] Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis
    Chirivella, Isabel
    Bermejo, Begona
    Insa, Amelia
    Alejandro Perez-Fidalgo, Jose
    Magro, Ana
    Rosello Keranen, Susana
    Martin, Paloma
    Bosch, Ana
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Neoadjuvant versus adjuvant chemotherapy with taxanes and anthracycline-based regimen: Which leads to better outcome in patients with different subtype breast cancer?
    Yang, Houpu
    Wang, Shu
    Zhou, Lixin
    Guo, Jiajia
    Cao, Yingming
    Zhou, Bo
    Cheng, Lin
    Xie, Fei
    Liu, Hongjun
    Tong, Fuzhong
    Liu, Miao
    Liu, Peng
    Wang, Siyuan
    Yang, Deqi
    Zhang, Jiaqing
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy
    Nikolenyi, Aliz
    Uhercsak, Gabriella
    Csenki, Melinda
    Hamar, Sandor
    Csoergo, Erika
    Tanczos, Ervin
    Thurzo, Laszlo
    Brodowicz, Thomas
    Wagnerova, Maria
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (01) : 61 - 68
  • [39] Docetaxel and anthracycline-based neoadjuvant chemotherapy in breast cancer
    Tiezzi, D. G.
    Andrade, J. M.
    Macchetti, A. H.
    Clagnan, W. S.
    Marana, H. R.
    Zola, F. E.
    Peria, F. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Vargas-Roig, L. M.
    Cuello-Carrion, F. D.
    Fernandez-Escobar, N.
    Daguerre, P.
    Leuzzi, M.
    Ibarra, J.
    Gago, F. E.
    Nadin, S. B.
    Ciocca, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345